DCM
SAGE

Dimension Capital Management’s Sage Therapeutics SAGE Stock Holding History

Dimension Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed -$296K – 89
2018
Q1 		$296K Buy
+1
New +$170 0.17% 74

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimension Capital Management's SAGE Position: Q2 2018 in Review

Dimension Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2018, closing a stake of 1 share — an estimated $296K sold.

Dimension Capital Management first reported a position in SAGE in Q1 2018 and held it in 1 quarter. The position peaked at $296K in Q1 2018. 269 funds tracked by Wall St. Rank hold SAGE as of Q2 2018.

  • Dimension Capital Management reported no remaining Sage Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Dimension Capital Management sold 1 Sage Therapeutics share in Q2 2018, an estimated $296K.
  • Dimension Capital Management first reported a position in Sage Therapeutics in Q1 2018 and held it in 1 quarter.
  • Dimension Capital Management's Sage Therapeutics position peaked at $296K in Q1 2018.
  • 269 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2018.

Based on Dimension Capital Management's 13F filing for Q2 2018, filed 27 Jul 2018.